Odonate starts Phase III trial of tesetaxel to treat breast cancer

Odonate Therapeutics Inc. (NASDAQ:ODT) began the Phase III CONTESSA trial of tesetaxel (DJ-927) to treat locally

Read the full 163 word article

User Sign In